In recent news, Allez Health, previously known as Zense-Life Inc., has successfully completed a $60 million Series A+ financing round. This funding was led by Osang Healthcare Co., Ltd., a strategic investor, with participation from existing investors.
The primary focus of Allez Health is on developing continuous glucose monitoring biosensor platforms that use sensor technology to analyze datasets across various health conditions. This ultimately leads to improved patient outcomes. The funds received will be used to support operations, regulatory approval filings, manufacturing scaling, and the acceleration of clinical trials.
The leadership team at Allez Health consists of former Dexcom executives, including CEO Leif Bowman, CTO Robert Boock, and CSO Ted Zhang. Bowman emphasized the importance of person-centric health and the company’s commitment to providing an accessible and reliable sensor for individuals looking to optimize their health. The company aims to bridge the gap between price and performance in the healthcare industry.
In a market snapshot, Dexcom recently received FDA clearance for its over-the-counter continuous glucose monitoring solution Stelo. Kakao Healthcare also introduced an AI-enabled mobile diabetes management app called PASTA, which connects to CGM devices like Dexcom’s G7, i-SENS’ CareSens Air, and the Mallya smart cap for insulin pens. These advancements in technology show a growing trend towards personalized and accessible healthcare solutions.
Allez Health’s mission is to revolutionize healthcare through innovative technology that improves patient outcomes while being accessible and affordable for everyone. With its focus on continuous glucose monitoring biosensor platforms and experienced leadership team, this California-based company is poised for success in the rapidly evolving healthcare industry.
